Search company, investor...

Wilmington Pharmaceuticals

Founded Year



Angel - II | Alive

Total Raised


Last Raised

$350K | 11 yrs ago

About Wilmington Pharmaceuticals

Wilmington Pharmaceuticals believes in fixing missed opportunities in established pharmaceutical products. With this product strategy, the company enjoys streamlined regulatory approval paths, relatively low R&D costs, and lower risks than traditional pharmaceutical product development programs. The company is currently completing the final clinical trial required for their initial product -- a fast dissolving version of a nausea and gastric distress product. This new product addresses proven market needs with improved delivery systems that are familiar to physicians and welcomed by patients. Wilmington Pharmaceuticals will begin work later this year on an improved version of a major pain drug.

Headquarters Location

1213 Culbreth Drive Suite 230

Wilmington, North Carolina, 28405,

United States


Missing: Wilmington Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Wilmington Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Wilmington Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Wilmington Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Wilmington Pharmaceuticals Patents

Wilmington Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Analgesics, Hepatotoxins, Propionic acids, Fluoroarenes, Pyridines


Application Date


Grant Date



Related Topics

Analgesics, Hepatotoxins, Propionic acids, Fluoroarenes, Pyridines



Wilmington Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Wilmington Pharmaceuticals founded?

    Wilmington Pharmaceuticals was founded in 2002.

  • Where is Wilmington Pharmaceuticals's headquarters?

    Wilmington Pharmaceuticals's headquarters is located at 1213 Culbreth Drive, Wilmington.

  • What is Wilmington Pharmaceuticals's latest funding round?

    Wilmington Pharmaceuticals's latest funding round is Angel - II.

  • How much did Wilmington Pharmaceuticals raise?

    Wilmington Pharmaceuticals raised a total of $2.95M.

  • Who are the investors of Wilmington Pharmaceuticals?

    Investors of Wilmington Pharmaceuticals include Wilmington Investor Network and Emergent Growth Fund.

  • Who are Wilmington Pharmaceuticals's competitors?

    Competitors of Wilmington Pharmaceuticals include Zogenix, Charleston Laboratories, Angstrom Pharmaceuticals, GC-Rise Pharmaceutical, SpiroGen and 13 more.

Compare Wilmington Pharmaceuticals to Competitors

Urigen Pharmacueticals

Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).

PetMedicus Labs

PetMedicus Labs is developing FDA-approved pharmaceuticals for the companion animal market.

IVREA Pharmaceuticals

IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.

The DNA Repair Company

The DNA Repair Company was founded to bring recent scientific discoveries from the Dana Farber Cancer Institute and the Massachusetts Institute of Technology to the clinic to benefit cancer patients. Breakthroughs in understanding DNA repair mechanisms have led to new personalized approaches to cancer treatment, beginning with diagnostic tools that improve the efficacy of currently available cancer therapies, as well as drugs under development. DNAR exists to make these tools available to physicians with the goal of improving clinical outcomes.

Morria Biopharmaceuticals

Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.